Delivery Order SPE2DB20D2014-SPE2DB25FC53Q
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,407.76 to AmerisourceBergen Drug Corp for Estrace 0.01% Cream in a 42.5-gram quantity. This contract, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was made competitively and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the...
- The Defense Logistics Agency awarded a $1,255 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 0.01% Estrace cream. As the prime contractor, Amerisourcebergen will supply 42.5 grams of the prescribed medication to the DLA for use in supporting the Department of Defense. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a two-day period in early September 2023. No subcontractors or set aside designations were identified. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Estradiol 0.01% Cream (42.5GM) on July 22, 2025, with a ceiling value of $1,150.32 and an ultimate completion date of July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- This is a Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,823.84, is for the delivery of Estrace 0.01% Cream, a pharmaceutical product used in medical care. The order has a performance period through July 15, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ESTRACE 0.01% CREAM 42.5GM, with a ceiling value of $1,617.10 and a period of performance through February 2025. This contract is a firm fixed-price, delivery order type, and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $140,000 to Amerisourcebergen Drug Corporation for the supply of Estrace 0.01% cream. As the prime contractor, Amerisourcebergen will deliver 42.5 grams of the specified medication to its place of performance in Conshohocken, Pennsylvania by the end date of August 29, 2023. The Defense Logistics Agency is the Department of Defense's combat logistics support agency, responsible for worldwide logistics...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed-price delivery order valued at approximately $630 to Amerisourcebergen Drug Corporation for Estrace 0.01% cream in 42.5 gram quantities. Performance will take place in Conshohocken, Pennsylvania under a one-day period from July 17-18, 2023. No additional details were provided regarding the original solicitation or whether this delivery order falls under a larger indefinite-delivery/indefinite-quantity contract vehicle. As...
- Defense Logistics Agency awarded a delivery order against an unspecified contract vehicle to Amerisourcebergen Drug Corp on October 12, 2023. The $580 firm fixed price order is for Estrace 0.01% cream supplied in 42.5 gram containers. Performance will occur in Conshohocken, Pennsylvania with an expected completion date of October 13, 2023. As no set-aside designation was used, this represents an open market procurement. Amerisourcebergen Drug Corp is a division of Amerisourcebergen...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,315.53 firm fixed price delivery order is for the pharmaceutical product Estrace 0.01% Cream, 42.5 gm. The contract has an ultimate completion date of October 21, 2024 and was awarded on October 18, 2024. This delivery order is associated with a larger $999,999,999 Indefinite Delivery...
- This $2,048.36 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of Estrace 0.01% Cream, a prescription pharmaceutical product, to support the medical needs of U.S. government agencies and healthcare programs. Amerisourcebergen, a major pharmaceutical distributor, holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC53QDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Estrace 0.01% Cream in a 42.5-gram quantity. This firm fixed-price delivery order, valued at $5,201.20, represents a non-competitive set-aside procurement and is scheduled for completion by July 23, 2025. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement needs, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements, from specialty medications and brand-name drugs to generic medications and medical supplies across multiple therapeutic domains. This delivery order for the hormone treatment Estrace reflects the company's ongoing role in supporting military medical supply chains through competitively awarded, firm fixed-price contracts with the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 7/22/25 |